
Alkermes (ALKS) Stock Forecast & Price Target
Alkermes (ALKS) Analyst Ratings
Bulls say
Alkermes PLC is experiencing a positive outlook due to the demonstrated efficacy of its product alixorexton, which has shown normalization across key wakefulness measures in patients with narcolepsy type 1 (NT1). The quantitative analyses have provided incremental confidence in the potential of alixorexton, particularly noting rapid normalization of the Epworth Sleepiness Scale (ESS) scores at week 2, with sustained responses during the open-label extension period. This efficacy not only underscores the product's therapeutic potential but also positions Alkermes favorably within the competitive landscape of unmet medical needs.
Bears say
Alkermes PLC's recent clinical data demonstrated mixed results for its product alixorexton, particularly related to the weekly cataplexy rate, which only achieved statistical significance at the 6mg dosage but showed variability due to outliers. The inconsistency in patient-reported outcomes raises concerns about the product's efficacy and marketability, potentially undermining investor confidence. Furthermore, the company's reliance on proprietary technologies and external partnerships for drug formulation may limit its control over product quality and therapeutic effectiveness, contributing to a negative outlook on its stock.
This aggregate rating is based on analysts' research of Alkermes and is not a guaranteed prediction by Public.com or investment advice.
Alkermes (ALKS) Analyst Forecast & Price Prediction
Start investing in Alkermes (ALKS)
Order type
Buy in
Order amount
Est. shares
0 shares